An Analysis of the SWOG S0500 Study
Robert McCormack, PhD, head, Technology Innovation, Janssen Diagnostics, LLC, discusses the SWOG S0500 study, which evaluated different treatments in patients with metastatic breast cancer who had elevated circulating tumor cell (CTC) levels.
Robert McCormack, PhD, head, Technology Innovation, Janssen Diagnostics, LLC, discusses the SWOG S0500 study, which evaluated different treatments in patients with metastatic breast cancer who had elevated circulating tumor cell (CTC) levels.
Clinical Pearls:
- The trial had three arms and enrolled patients with metastatic breast cancer that were about to start first-line chemotherapy treatment
- The patients were given a screening CTC test with CellSearch prior to the start of their treatment
- Patients with less than 5 CTCs were put in arm A while patients with more than 5 CTCs received their chemotherapy treatment for three weeks before receiving another CTC test
- The patients whose CTC levels dropped after three weeks were placed in arm B while the patients whose CTC levels did not drop after three weeks were placed in arm C
- Patients in arm C were either randomized to continue their current treatment or were switched to the next line of chemotherapy
- Results showed that after three weeks of therapy, a survival benefit can be determined based on CTC levels
Batalini Explores Role of UGT1A1 in Patients Treated With Sacituzumab Govitecan for HR+ MBC
April 22nd 2024During a Community Case Forum live event in partnership with The Arizona Clinical Oncology Society, Felipe Batalini, MD, discussed the TROPiCS-02 trial of sacituzumab govitecan and the impact of the UGT1A1 status on adverse event frequency.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
